Skip to main content

Compare Stocks

Date Range: 

 AbcamSana BiotechnologyCronos GroupGenusAbcam
SymbolNASDAQ:ABCMNASDAQ:SANATSE:CRONLON:GNSLON:ABC
Price Information
Current Price$20.11$20.00C$8.81GBX 4,750GBX 1,402
52 Week RangeHoldBuyBuyBuyHold
MarketRank™
Overall Score1.11.20.91.30.5
Analysis Score1.23.32.31.31.1
Community Score2.42.52.12.71.3
Dividend Score0.00.00.00.80.0
Ownership Score0.00.00.01.70.0
Earnings & Valuation Score1.90.00.00.00.0
Analyst Ratings
Consensus RecommendationHoldBuyBuyBuyHold
Consensus Price Target$22.00$40.00C$9.57GBX 4,760GBX 1,402
% Upside from Price Target9.40% upside100.00% upside8.59% upside0.21% upsideN/A
Trade Information
Market Cap$4.56 billion$3.75 billionC$3.27 billion£3.10 billion£3.18 billion
BetaN/AN/AN/AN/AN/A
Average Volume171,297587,628877,988105,596443,731
Sales & Book Value
Annual RevenueN/AN/AC$46.72 million£566.40 million£269.30 million
Price / SalesN/AN/A70.085.4811.80
CashflowN/AN/AC$3.37 per shareGBX 75.98 per shareGBX 91.97 per share
Price / CashN/AN/A2.6162.5115.24
Book ValueN/AN/AC$4.75 per shareGBX 769.20 per shareGBX 286.70 per share
Price / BookN/AN/A1.850.060.05
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSN/AN/AC($0.26)GBX 73.60GBX (0.90)
Trailing P/E Ratio0.000.00N/A64.54N/A
Forward P/E Ratio64.87
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AGBX 0.29GBX 0.04
Dividend YieldN/AN/AN/A0.01%0.00%
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/A0.40%N/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A0.58%28.59%18.58%
Current RatioN/AN/A6.63%1.86%5.58%
Quick RatioN/AN/A6.33%1.26%4.79%
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
Employees1,6002636313,1001,600
Shares Outstanding226.72 million187.68 million371.66 million65.31 million226.73 million
Next Earnings DateN/A8/4/2021 (Estimated)N/AN/AN/A
OptionableNot OptionableNot OptionableOptionableNot OptionableOptionable
SourceHeadline
Abcam plc (LON:ABC) Receives Consensus Rating of "Hold" from AnalystsAbcam plc (LON:ABC) Receives Consensus Rating of "Hold" from Analysts
americanbankingnews.com - May 16 at 4:10 AM
Epigenetic Market 2021 Size : Global Key Findings, Industry Demand, Regional Analysis, Key Players Profiles, Future Prospects and Forecasts to 2027Epigenetic Market 2021 Size : Global Key Findings, Industry Demand, Regional Analysis, Key Players Profiles, Future Prospects and Forecasts to 2027
marketwatch.com - May 15 at 12:43 PM
Abcam (LON:ABC) Share Price Crosses Below 200-Day Moving Average of $1,515.15Abcam (LON:ABC) Share Price Crosses Below 200-Day Moving Average of $1,515.15
americanbankingnews.com - May 15 at 1:58 AM
Kinetin Market Giants To Grow At Much Faster Pace | Thermo Fisher Scientific, Cayman Chemical, Selleck Chemicals, Abcam, Gold Biotechnology, MerckKinetin Market Giants To Grow At Much Faster Pace | Thermo Fisher Scientific, Cayman Chemical, Selleck Chemicals, Abcam, Gold Biotechnology, Merck
industribune.net - May 14 at 4:39 PM
An aged immune system drives senescence and ageing of solid organsAn aged immune system drives senescence and ageing of solid organs
nature.com - May 12 at 3:25 PM
Human urine-derived stem cell-derived exosomal miR-21-5p promotes neurogenesis to attenuate Rett syndrome via the EPha4/TEK axisHuman urine-derived stem cell-derived exosomal miR-21-5p promotes neurogenesis to attenuate Rett syndrome via the EPha4/TEK axis
nature.com - May 11 at 7:46 AM
Galactosyl Transferases market set to touch double digit cagr | Abgent, R&D Systems, St John’s Laboratory, RayBiotech, Novus Biologicals, CovalabGalactosyl Transferases market set to touch double digit cagr | Abgent, R&D Systems, St John’s Laboratory, RayBiotech, Novus Biologicals, Covalab
industribune.net - May 6 at 3:52 PM
Abcam (LON:ABC) Share Price Passes Below Two Hundred Day Moving Average of $1,502.95Abcam (LON:ABC) Share Price Passes Below Two Hundred Day Moving Average of $1,502.95
americanbankingnews.com - April 29 at 2:57 AM
Ubiquitin Enzymes Market Analysis 2021 : Market Size, Growth, Trends, Opportunities Forecast To 2026 with Top Countries DataUbiquitin Enzymes Market Analysis 2021 : Market Size, Growth, Trends, Opportunities Forecast To 2026 with Top Countries Data
marketwatch.com - April 28 at 12:29 PM
Trypsin Inhibitor Market Research Reports 2021- Industry Size, In-Depth Qualitative Insights, Explosive Growth Opportunity, Regional Analysis 2027Trypsin Inhibitor Market Research Reports 2021- Industry Size, In-Depth Qualitative Insights, Explosive Growth Opportunity, Regional Analysis 2027
marketwatch.com - April 27 at 11:24 AM
MicroRNM Market 2021 Top Companies report covers are Abcam Plc,Illumina, Inc.,Agilent Technologies,Bio- and Market Share, Demand Forecast to 2025MicroRNM Market 2021 Top Companies report covers are Abcam Plc,Illumina, Inc.,Agilent Technologies,Bio- and Market Share, Demand Forecast to 2025
marketwatch.com - April 21 at 7:00 AM
Abcam plc (LON:ABC) Given Average Recommendation of "Hold" by BrokeragesAbcam plc (LON:ABC) Given Average Recommendation of "Hold" by Brokerages
americanbankingnews.com - April 21 at 5:12 AM
Antibody Services Market Next Big Thing : Major Giants- ThermoFisher, GenScript, AbcamAntibody Services Market Next Big Thing : Major Giants- ThermoFisher, GenScript, Abcam
sbwire.com - April 20 at 3:54 PM
Immunoassay Kits Market Size 2021 Research Report by Direct Sales, Distributor, Trends, Product Type Detail and Forecast to 2025Immunoassay Kits Market Size 2021 Research Report by Direct Sales, Distributor, Trends, Product Type Detail and Forecast to 2025
marketwatch.com - April 19 at 12:42 PM
In situ architecture of neuronal α-Synuclein inclusionsIn situ architecture of neuronal α-Synuclein inclusions
nature.com - April 14 at 9:39 AM
Trypsin Inhibitor Market to Deliver Prominent Growth & Striking Opportunities, Analysis, Demand, Growth by Top Key Players, Forecast 2026Trypsin Inhibitor Market to Deliver Prominent Growth & Striking Opportunities, Analysis, Demand, Growth by Top Key Players, Forecast 2026
marketwatch.com - April 12 at 12:45 PM
Reovirus directly engages integrin to recruit clathrin for entry into host cellsReovirus directly engages integrin to recruit clathrin for entry into host cells
nature.com - April 12 at 12:45 PM
Tangeretin Market Size 2021 by Market Estimates and Projections by Types, Applications, Trends and Forecast to 2027Tangeretin Market Size 2021 by Market Estimates and Projections by Types, Applications, Trends and Forecast to 2027
marketwatch.com - April 9 at 8:50 AM
Cambridge A-listers combine in SARS-CoV-2 moveCambridge A-listers combine in SARS-CoV-2 move
businessweekly.co.uk - April 7 at 9:27 AM
Avacta Group signs deal to help scientists who are fighting the coronavirus pandemicAvacta Group signs deal to help scientists who are fighting the coronavirus pandemic
yorkshirepost.co.uk - April 6 at 7:19 AM
Avacta Group In Deal With ABCAM To Sell SARS-CoV-2 Spike Protein Affimer Reagents- Quick FactsAvacta Group In Deal With ABCAM To Sell SARS-CoV-2 Spike Protein Affimer Reagents- Quick Facts
markets.businessinsider.com - April 6 at 7:19 AM
Avacta Announces Distribution Agreement With ABCAM plcAvacta Announces Distribution Agreement With ABCAM plc
finance.yahoo.com - April 6 at 7:19 AM
SENP1-mediated deSUMOylation of JAK2 regulates its kinase activity and platinum drug resistanceSENP1-mediated deSUMOylation of JAK2 regulates its kinase activity and platinum drug resistance
nature.com - April 1 at 2:24 PM
Global Biomarkers Market (2021 to 2025) - Featuring 10X Genomics, Abbott Laboratories & Abcam Among Others - ResearchAndMarkets.comGlobal Biomarkers Market (2021 to 2025) - Featuring 10X Genomics, Abbott Laboratories & Abcam Among Others - ResearchAndMarkets.com
finance.yahoo.com - March 31 at 9:46 AM
Abcam PLC Stock Shows Every Sign Of Being Fairly ValuedAbcam PLC Stock Shows Every Sign Of Being Fairly Valued
gurufocus.com - March 30 at 5:39 AM
DateCompanyBrokerageAction
3/15/2021AbcamSVB LeerinkLower Price Target
3/12/2021AbcamBerenberg BankReiterated Rating
3/9/2021AbcamJPMorgan Chase & Co.Reiterated Rating
3/9/2021AbcamRoyal Bank of CanadaReiterated Rating
1/28/2021AbcamMorgan StanleyInitiated Coverage
11/16/2020AbcamWilliam BlairInitiated Coverage
11/16/2020AbcamBank of AmericaInitiated Coverage
3/8/2021Sana BiotechnologyThe Goldman Sachs GroupInitiated Coverage
5/11/2021Cronos GroupCowenLower Price Target
5/11/2021Cronos GroupMKM PartnersBoost Price Target
5/10/2021Cronos GroupRaymond JamesBoost Price Target
5/10/2021Cronos GroupStifel NicolausLower Price Target
4/9/2021Cronos GroupJefferies Financial GroupBoost Price Target
3/2/2021Cronos GroupPi FinancialBoost Price Target
3/31/2020Cronos GroupCanaccord GenuityDowngrade
1/18/2021GenusLiberum CapitalBoost Price Target
6/30/2020GenusPeel HuntReiterated Rating
4/1/2020GenusHSBCBoost Price Target
11/14/2019GenusPeel HuntReiterated Rating
(Data available from 5/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.